New spectrophotometric techniques for the estimation of osimertinib mesylate mesylate in tablet dosage form
Osimertinib Mesylate is used for a treatment of non small cell lung cancer (NSCLC). Whereas only few simple, precise and accurate spectrophotometric methods were developed for the determination of Osimertinib Mesylate (tagrisso) in pharmaceutical dosage forms. The absorption maxima was found to be at 267 nm in method A (0.1N HCl) and shows linearity over the concentration range of 0.002-0.02 µg/mL with regression equation y=0.4323x + 0.0104 (r2 = 0.9992). In Method B (Sodium acetate buffer, pH 4.5) the drug obeys Beer Lambert’s law (λmax267nm) in the concentration range of 0.002-0.02 µg/mL with regression equation y=0.484x-0.017(r2= 0.9992). In Method C (phosphate buffer, pH 7.2) the drug obeys Beer Lambert’s law (λmax267nm) in the concentration range of 0.002-0.02 µg/mL with regression equation y=0.2949x+0.0108(r2= 0.9992) In Method D (Methanol ) the drug obeys Beer Lambert’s law (λmax267nm) in the concentration range of 0.002-0.02 µg/mL with regression equation y=0.6323x+0.003 (r2= 0.999). 1st derivative spectrophotometric method (E, F, G and H) were developed in 0.1NHCl and Sodium acetate pH 4.5 and phosphate buffer pH 7.2 and methanol in which Osimertinib Mesylate obeys Beer Lambert’s law 0.002-0.02 µg/mL and 0.002-0.02 µg/mL and 0.002-0.02 µg/mL and 0.002-0.02 µg/mL with regression equations y=0.0259x + 0.0008 and y=0.0137x - 0.0005 and y=0.0097x-0.0008 and y=0.0087-0.0007 respectively. The proposed spectrophotometric method was validated as per the ICH guidelines and can be applied for the determination of Osimertinib Mesylate in pharmaceutical formulations. Osimertinib Mesylate, Derivative spectroscopy, Spectrophometry, Validation, Tagrisso.
Keywords: Tagrisso, Osimertinib Mesylate, Derivative spectroscopy, Spectrophometry, Validation.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).